TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01512056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdimFlu-S
Description: All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
Study: NCT00073073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: exemestane 25 mg by mouth (PO) every day for two years

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: calcium carbonate 1200 mg PO every day x 2 years

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 400 international units PO every day x 2 years
Study: NCT02328911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
Study: NCT04014023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DWP16001 placebo-matching tablets
Study: NCT04411082

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of once daily Placebo
Study: NCT04071691

Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI
Description: SST2 PET-MRI scan

Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI
Description: SST2 PET-MRI scan
Study: NCT04107103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: Nivolumab with Pemetrexed
Description: Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
Study: NCT02491411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT00692900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous docetaxel with intraperitoneal oxaliplatin
Description: IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
Study: NCT02752971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac
Study: NCT02491411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02802020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic fully-covered self-expanding metal stent (FCSEMS)
Description: The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
Study: NCT03088540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
Study: NCT00692900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous oxaliplatin with intraperitoneal docetaxel
Description: IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
Study: NCT03088540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered with either Pemetrexed, Paclitaxel or gemcitabine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered with either Pemetrexed, Paclitaxel or gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Patients will be administered cemiplimab as per protocol.
Study: NCT03852888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level
Description: Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
Study: NCT02791789

Intervention type: OTHER
Group type: OTHER
Intervention: Autism Spectrum Disorder
Description: Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
Study: NCT04727710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: A self-directed, web-based mindfulness training. Investigators recommend one module a week for 6 weeks. Each module is approximately 1 hour long and consists of didactic components as well as meditation and mindfulness exercises.
Study: NCT02920047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan + Amlodipine
Description: Treatment A
Study: NCT06372080

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistance training with hydrolyzed collagen ingestion in healthy young men
Description: Participants in this intervention will be healthy young men. The information of nutritional supplements is below.~Hydrolyzed collagen: 30 grams unflavored hydrolysed collagen (HC) (Myprotein, Cheshire, UK) 30.5 grams unflavored maltodextrin (Myprotein, Cheshire, UK) 50 milligrams vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK) 3 grams non-caloric sweetener (Truvia®, SilverSpoon, London, UK)
Study: NCT04105543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 131
Description: CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
Study: NCT06372080

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistance training with hydrolyzed collagen ingestion in healthy young women
Description: Participants in this intervention will be healthy young women. The same nutritional supplements in Arm 1 wil be used in Arm 2.
Study: NCT03975179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of intraoperative frozen section biopsy for margin status
Description: Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frozen section biopsy for margin status
Description: Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
Study: NCT00370955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification using either high vacuum or low vacuum techniques
Description: All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
Study: NCT03415477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (Xgeva)
Description: Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
Study: NCT01347086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo (low dose)
Description: single dose of matching placebo
Study: NCT04727710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard pre-operative survivorship seminar, offered monthly to all patients at Michigan Medicine about to undergo prostatectomy and their partners is aimed at promoting realistic expectations of prostatectomy outcomes, typical side effects, rehabilitation and emotional adjustment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard pre-operative survivorship seminar, offered monthly to all patients at Michigan Medicine about to undergo prostatectomy and their partners is aimed at promoting realistic expectations of prostatectomy outcomes, typical side effects, rehabilitation and emotional adjustment.
Study: NCT01938664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan with CBT
Description: 8 mg, po (by mouth)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with CBT
Study: NCT02210273

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solace Bladder Control (Vesair) Balloon
Description: Subjects may undergo treatment every 12 months until study completion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solace Bladder Control (Vesair) Balloon
Description: Subjects may undergo treatment every 12 months until study completion.
Study: NCT02486705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Family Coach Full
Description: PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
Study: NCT04143542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trunk blocks
Description: Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trunk blocks
Description: Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
Study: NCT02267863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APTO-253
Description: APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
Study: NCT00055419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
Study: NCT02486705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Family Coach Basic
Description: PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
Study: NCT04689165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group A meningococcal polysaccharide vaccine
Description: Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group A meningococcal polysaccharide vaccine
Description: Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
Study: NCT02401399

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Regular diet
Description: The patients receive regular diet 900 Kcal/day during 15 days before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High protein formula
Description: The patients receive high protein formula during 15 days before surgery
Study: NCT01347086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA (medium dose)
Description: Single does of BI 207127 NA
Study: NCT02401399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: The patients receive Immunonutrition formula during 15 days before surgery
Study: NCT03185429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Specific Antigen-loaded Dendritic Cells
Description: Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 by vein before the first cell infusion.
Study: NCT03645603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
Study: NCT00924664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 20 mg
Description: Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Description: Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
Study: NCT01598987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Description: Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m\^2/dose in combination wit Cyclosporine A or 2.0 mg/m\^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
Study: NCT02395185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk bottle administration
Description: Patients are given a bottle of milk during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk bottle administration
Description: Patients are given a bottle of milk during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk bottle administration
Description: Patients are given a bottle of milk during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water bottle administration
Description: Patients are given a bottle of water during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water bottle administration
Description: Patients are given a bottle of water during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water bottle administration
Description: Patients are given a bottle of water during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose bottle administration
Description: Patients are given a bottle of sucrose during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose bottle administration
Description: Patients are given a bottle of sucrose during the casting process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose bottle administration
Description: Patients are given a bottle of sucrose during the casting process.
Study: NCT01097980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00006221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Study: NCT01347086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA (low dose)
Description: single dose of BI 207127 NA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo (medium dose)
Description: Single dose of matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA (high dose)
Description: Single dose of BI 207127 NA
Study: NCT00683358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1-A24-1084 (SYGVLLWEI)
Description: HLA-A\*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
Study: NCT03651999

Intervention type: OTHER
Intervention: participation in a workshop: dream workshop animated by a nurse anesthesist
Description: After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
Study: NCT03206944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomato Fruit Extract
Description: Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
Study: NCT03521167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
Study: NCT02210273

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Solace Sham Treatment
Description: Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
Study: NCT01347086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo (high dose)
Description: Single dose of matching placebo
Study: NCT03766906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talk STEM Familia app
Description: The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
Study: NCT02090894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV Light (Laser Genesis)
Study: NCT02188342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT
Description: 12 HIT exercise sessions in 31 days on a stationary cycle ergometer
Study: NCT01786265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given via injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Given PO
Study: NCT02288923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration Analgesia
Description: Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
Study: NCT01786265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Given PO